Unlocking the Immune Brain. Combination Immunotherapy. Finally Solved by Programming  Myeloid Cells.

Because they’re the only compartment that can coordinate an entire immune response at once. In peacetime, immunity runs decentralized. Under threat, hierarchies appear — and myeloid cells are the control layer they form around: priming T cells, conditioning them, recruiting reinforcements, setting the cytokine milieu, seeding memory. Other compartments can turn a tumbler or two. Only myeloid cells turn them all at once.

Because a cure is a control problem, not a drug problem. Cancer is like a combination lock with five tumblers: neoantigen priming, T-cell conditioning, checkpoint release, cytokines and the TME, immune memory. Current therapies pick one at a time. The tumor jams all five — by seizing the layer that coordinates your immune response. Solid tumors converge on the same trick: seize the myeloid layer and the response goes dark. A coordinated system can’t be beaten with uncoordinated drugs. All five tumblers have to turn at once, without the toxicity of forcing them. The tumor proved the operating system exists. By stealing it. IBOS steals it back — and makes it controllable.

Our risk sits in the engineering, not the biology. Most cancer drugs begin with an unproven molecule and hope it translates. Roughly one in eight immuno-oncology programs makes it from Phase 1 to approval — twice the oncology average. We start further down that road: with biology the tumor itself has proven, made programmable. Engineering risk you can iterate on early. Biology risk you discover in Phase 2.

A German biotech company that does most of its work in America. Headquartered in Germany. Operations run with partners in the U.S. (Yale University and Emory University) where the science came from, and where the clinical path runs. A significant patent portfolio of globally granted and pending families cover the technology.

The Gates Foundation funds our work on enhancing mRNA vaccination against antigenic threats. ARPA-H committed $25 million through the Cancer Moonshot. The science team is first-in-class, out of Yale and Emory. Institutions that fund fundamentals, not stories.

Justin Duckworth leads as CEO, with Dr Guenter Bauer as CTO and Olga Sobolev as VP Immunology. Our main investor is Dr Karsten Henco, who Co-founded Qiagen, Evotec and Neurimmune among others.
Our two lead scientists whose work this stands on: Professor Richard Edelson at Yale, Professor Philip Santangelo at Emory.